Sanofi Pasteur clinical trials

Acquired by Sanofi, Aug 20, 2004 · source ↗

The registry lists 374 studies whose lead sponsor is Sanofi Pasteur. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 374. List all 374 → · All Sanofi studies →

• Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcneRecruitingNCT06316297Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild AcneRecruitingNCT07013747Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Dengvaxia US Pregnancy RegistryRecruitingNCT04486638

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)RecruitingNCT04843111

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and ToddlersCompletedNCT06284915Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminatedNCT06397768Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USAActive, not recruitingNCT04942210Phase 2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as ToddlersActive, not recruitingNCT04936685Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and OlderCompletedNCT05639894Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and AboveCompletedNCT06361875Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminatedNCT06705140Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German InfantsCompletedNCT06824207

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 YearsActive, not recruitingNCT07536048

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06744205Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and OlderTerminatedNCT04904549Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and AsiaActive, not recruitingNCT05011123Phase 2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and OlderCompletedNCT06604767Phase 1

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and OlderCompletedNCT06727058Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingNCT06736041Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidateCompletedNCT06134648Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and OlderCompletedNCT06251024Phase 2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German ParticipantsCompletedNCT06800885

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of KoreaCompletedNCT06793826

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of AdultsCompletedNCT04127786Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminatedNCT06252285Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Phase 3 Single Arm, Open Study on vYF in AdultsCompletedNCT07222059Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)CompletedNCT05687279Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaCompletedNCT05794230Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingNCT06647407Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and AdolescentsCompletedNCT06128733Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of AgeTerminatedNCT04544267Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderActive, not recruitingNCT06686654Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of AgeCompletedNCT06641180Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of AgeCompletedNCT06582056Not applicable

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 YearsCompletedNCT06583031Phase 1

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)CompletedNCT06325332

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and InfantsTerminatedNCT04825223Phase 1

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of LifeCompletedNCT05437510Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsActive, not recruitingNCT06838000Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and OlderCompletedNCT04537234Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and OlderCompletedNCT05608005Phase 1/2

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and OlderCompletedNCT04498832Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in AdultsCompletedNCT04142086Phase 1

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompletedNCT04429295Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in InfancyCompletedNCT05929651Phase 4

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in ThaïlandCompletedNCT04478084Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in ThaïlandCompletedNCT04594551Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and OlderCompletedNCT04762680Phase 2/3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in AdultsCompletedNCT03965962Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi

• Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in VietnamCompletedNCT06228586Phase 3

  Sponsor listed in the registry: Sanofi Pasteur, a Sanofi Company · First submitted after Sanofi Pasteur became part of Sanofi